Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q3 FY25
Discovery themes featuring this stockDr Agarwals Health Care Ltd (AGARWALEYE) is currently trading at 480.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Dr. Agarwal's Health Care Limited is India's largest eye care services chain, providing comprehensive medical services for ocular health including consultations, surgeries, and specialized treatments. The company experienced strong financial performance with a 20.8% revenue growth YTD December 2025, driven by the expansion of operational facilities and introduction of advanced surgical technologies. Strategic investments in robotic surgery technologies like Femto Cataract and advanced equipment in centers like Gurgaon and Vashi underline its focus on cutting-edge innovations. Expansive network growth is evidenced via 38 new facilities added, enhancing service capacity across Tier-I and non-metro cities by adopting a hub-and-spoke model. The southern region remains a core market, contributing 63% of revenues, while New Delhi and Maharashtra bolster future growth potential with recent facility commissions.
Over the past 52 weeks, Dr Agarwals Health Care Ltd has traded between a low of ₹402.10 and a high of ₹567.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Dr Agarwals Health Care Ltd has a market capitalization of approximately 15,336.14. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Dr Agarwals Health Care Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 115.14 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 15,336.14 Cr, Dr Agarwals Health Care Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Dr Agarwals Health Care Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Dr Agarwals Health Care Ltd is 115.14. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The Uniresearch trailing-growth estimate pegs Q1 FY27 revenue at ₹565-650 crore, based on a Q1 FY26 base of ₹501 crore.
Equity shareholders and unsecured creditors will vote on a Scheme of Amalgamation to merge Dr. Agarwal’s Eye Hospital Limited into Dr. Agarwals Health Care Limited, as directed by the NCLT.
The company statement cited consolidated Q4 FY26 net profit of INR 50 crore, up 17.4% year-on-year from INR 43 crore.
PAT for the year ended March 31, 2026 was ₹168 Cr, up 52.4% year-on-year.
Bearish
3
Neutral
8
Bullish
3
Bearish
20
Neutral
8
Bullish
18
Bearish
17
Neutral
0
Bullish
15
Neutral
Neutral
8
8
Bullish
3
Bullish
3
Bearish
17
Neutral
0
Bullish
15
Bearish
17
Neutral
0
Bullish
15
Bearish
17
Neutral
0
Bullish
15
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1550.20 | 15,665 Cr | 54.89 | 9.38 | 0.23 | 16.89 | 16.88 | 10.46 | ||
480.95 | 15,336 Cr | 115.14 | 7.57 | 0.00 | 6.58 | 9.75 | 4.27 | ||
287.65 | 12,424 Cr | 48.99 | 6.18 | 0.00 | 12.77 | 17.33 | 9.55 | ||
317.35 | 10,404 Cr | 55.46 | 6.74 | 0.06 | 12.56 | 13.77 | 7.88 | ||
670.20 | 10,019 Cr | 728.12 | 7.52 | 0.00 | 2.90 | 7.81 | 0.58 | ||
831.70 | 8,038 Cr | 45.63 | 4.51 | 0.00 | 9.85 | 11.09 | 7.50 | ||
5825.00 | 6,389 Cr | 26.13 | 4.84 | 0.26 | 18.53 | 20.76 | 11.83 | ||
| Median: 7 Co. | — | 670.20 | 10,404 Cr | 54.89 | 6.74 | 0.00 | 12.56 | 13.77 | 7.88 |
Dr. Agarwal's Health Care Limited is India's largest eye care services chain, providing comprehensive medical services for ocular health including consultations, surgeries, and specialized treatments.
The company experienced strong financial performance with a 20.8% revenue growth YTD December 2025, driven by the expansion of operational facilities and introduction of advanced surgical technologies.
Strategic investments in robotic surgery technologies like Femto Cataract and advanced equipment in centers like Gurgaon and Vashi underline its focus on cutting-edge innovations.
Expansive network growth is evidenced via 38 new facilities added, enhancing service capacity across Tier-I and non-metro cities by adopting a hub-and-spoke model.
The southern region remains a core market, contributing 63% of revenues, while New Delhi and Maharashtra bolster future growth potential with recent facility commissions.
Healthcare Services
Hospital
15,336 Cr
Low Risk
115.1
64.4
3.1
7.6
567.80
402.10
Sales CAGR
Profit CAGR
ROE
ROCE
